Monday, February 11, 2019

Guide to Efficacy Analysis in Solid Tumors Oncology Clinical Trials

Meet Anastasiia Tiurdo

Anastasiia Tiurdo has been working as a Statistical Programming Analyst at Intego Group for the last 4 years, including 3 years of continuous experience in Oncology Clinical Trials. She received her Master’s Degree in Applied Mathematics from Karazin Kharkiv National University, and got her SAS Certification after graduating the Biostatistical University training program. Anastasiia mainly uses SAS in her day-to-day job and is particularly interested in Statistics.  She likes doing yoga in her leisure time and dreams to visit Iceland to see the Northern Lights.

Introduction to Step by Step guide to efficacy analysis in Solid Tumors Oncology Clinical Trials

Cancer is a scourge of the modern society, so more and more pharmaceutical companies work on discovering a treatment that will fight against the different types of this disease. Nowadays the majority of clinical trials evaluating cancer treatments for the objective response in solid tumors use a set of rules called R.E.C.I.S.T. This abbreviation is commonly used in a clinical programmer’s daily routine, but not everyone has a deep understanding of the R.E.C.I.S.T. requirements. This paper provides a simple step by step description of the R.E.C.I.S.T. compliant efficacy analysis in solid tumors oncology studies starting from the data collection by an investigator up to the final statistical results based on this data.

Stay in touch

Get connected with Intego, and let us know how we can help.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intego Insights